BACKGROUND: Individual magnetic resonance imaging (MRI) disease severity measures, such as atrophy or lesions, show weak relationships to clinical status in patients with multiple sclerosis (MS). OBJECTIVE: To combine MS-MRI measures of disease severity into a composite score. DESIGN: Retrospective analysis of prospectively collected data. SETTING: Community-based and referral subspecialty clinic in an academic hospital. PATIENTS: A total of 103 patients with MS, with a mean (SD) Expanded Disability Status Scale (EDSS) score of 3.3 (2.2), of whom 62 (60.2%) had the relapsing-remitting, 33 (32.0%) the secondary progressive, and 8 (7.8%) the primary progressive form. MAIN OUTCOME MEASURES: Brain MRI measures included baseline T2 hyperintense (T2LV) and T1 hypointense (T1LV) lesion volume and brain parenchymal fraction (BPF), a marker of global atrophy. The ratio of T1LV to T2LV (T1:T2) assessed lesion severity. A Magnetic Resonance Disease Severity Scale (MRDSS) score, on a continuous scale from 0 to 10, was derived for each patient using T2LV, BPF, and T1:T2. RESULTS: The MRDSS score averaged 5.1 (SD, 2.6). Baseline MRI and EDSS correlations were moderate for BPF, T1:T2, and MRDSS and weak for T2LV. The MRDSS showed a larger effect size than the individual MRI components in distinguishing patients with the relapsing-remitting form from those with the secondary progressive form. Models containing either T2LV or MRDSS were significantly associated with disability progression during the mean (SD) 3.2 (0.3)-year observation period, when adjusting for baseline EDSS score. CONCLUSION: Combining brain MRI lesion and atrophy measures can predict MS clinical progression and provides the basis for developing an MRI-based continuous scale as a marker of MS disease severity.
BACKGROUND: Individual magnetic resonance imaging (MRI) disease severity measures, such as atrophy or lesions, show weak relationships to clinical status in patients with multiple sclerosis (MS). OBJECTIVE: To combine MS-MRI measures of disease severity into a composite score. DESIGN: Retrospective analysis of prospectively collected data. SETTING: Community-based and referral subspecialty clinic in an academic hospital. PATIENTS: A total of 103 patients with MS, with a mean (SD) Expanded Disability Status Scale (EDSS) score of 3.3 (2.2), of whom 62 (60.2%) had the relapsing-remitting, 33 (32.0%) the secondary progressive, and 8 (7.8%) the primary progressive form. MAIN OUTCOME MEASURES: Brain MRI measures included baseline T2 hyperintense (T2LV) and T1 hypointense (T1LV) lesion volume and brain parenchymal fraction (BPF), a marker of global atrophy. The ratio of T1LV to T2LV (T1:T2) assessed lesion severity. A Magnetic Resonance Disease Severity Scale (MRDSS) score, on a continuous scale from 0 to 10, was derived for each patient using T2LV, BPF, and T1:T2. RESULTS: The MRDSS score averaged 5.1 (SD, 2.6). Baseline MRI and EDSS correlations were moderate for BPF, T1:T2, and MRDSS and weak for T2LV. The MRDSS showed a larger effect size than the individual MRI components in distinguishing patients with the relapsing-remitting form from those with the secondary progressive form. Models containing either T2LV or MRDSS were significantly associated with disability progression during the mean (SD) 3.2 (0.3)-year observation period, when adjusting for baseline EDSS score. CONCLUSION: Combining brain MRI lesion and atrophy measures can predict MS clinical progression and provides the basis for developing an MRI-based continuous scale as a marker of MS disease severity.
Authors: L D Jacobs; R W Beck; J H Simon; R P Kinkel; C M Brownscheidle; T J Murray; N A Simonian; P J Slasor; A W Sandrock Journal: N Engl J Med Date: 2000-09-28 Impact factor: 91.245
Authors: J S Wolinsky; P A Narayana; J H Noseworthy; F D Lublin; J N Whitaker; A Linde; P Gjörstrup; H C Sullivan Journal: Neurology Date: 2000-05-09 Impact factor: 9.910
Authors: G R Cutter; M L Baier; R A Rudick; D L Cookfair; J S Fischer; J Petkau; K Syndulko; B G Weinshenker; J P Antel; C Confavreux; G W Ellison; F Lublin; A E Miller; S M Rao; S Reingold; A Thompson; E Willoughby Journal: Brain Date: 1999-05 Impact factor: 13.501
Authors: C Mainero; N De Stefano; G Iannucci; M P Sormani; L Guidi; A Federico; M L Bartolozzi; G Comi; M Filippi Journal: Neurology Date: 2001-05-22 Impact factor: 9.910
Authors: L D Jacobs; K E Wende; C M Brownscheidle; B Apatoff; P K Coyle; A Goodman; M H Gottesman; C V Granger; S J Greenberg; J Herbert; L Krupp; N S Lava; C Mihai; A E Miller; A Perel; C R Smith; D H Snyder Journal: Mult Scler Date: 1999-10 Impact factor: 6.312
Authors: Elizabeth Fisher; Ansi Chang; Robert J Fox; Jean A Tkach; Therese Svarovsky; Kunio Nakamura; Richard A Rudick; Bruce D Trapp Journal: Ann Neurol Date: 2007-09 Impact factor: 10.422
Authors: Paolo Invernizzi; Laura Bertolasi; Maria Rachele Bianchi; Marco Turatti; Alberto Gajofatto; Maria Donata Benedetti Journal: J Neurol Date: 2011-04-09 Impact factor: 4.849
Authors: Jennifer Moodie; Brian C Healy; Guy J Buckle; Susan A Gauthier; Bonnie I Glanz; Ashish Arora; Antonia Ceccarelli; Shahamat Tauhid; Xue-Mei Han; Arun Venkataraman; Tanuja Chitnis; Samia J Khoury; Charles R G Guttmann; Howard L Weiner; Mohit Neema; Rohit Bakshi Journal: J Neurol Sci Date: 2011-12-28 Impact factor: 3.181
Authors: Maria Di Gregorio; Lorenzo Gaetani; Paolo Eusebi; Piero Floridi; Antonella Picchioni; Giovanni Rosi; Andrea Mancini; Chiara Floridi; Francesca Baschieri; Lucia Gentili; Paola Sarchielli; Paolo Calabresi; Massimiliano Di Filippo Journal: J Neurol Date: 2018-01-11 Impact factor: 4.849
Authors: A Ceccarelli; J S Jackson; S Tauhid; A Arora; J Gorky; E Dell'Oglio; A Bakshi; T Chitnis; S J Khoury; H L Weiner; C R G Guttmann; R Bakshi; M Neema Journal: AJNR Am J Neuroradiol Date: 2012-03-29 Impact factor: 3.825
Authors: Keren Regev; Brian C Healy; Fariha Khalid; Anu Paul; Renxin Chu; Shahamat Tauhid; Subhash Tummala; Camilo Diaz-Cruz; Radhika Raheja; Maria A Mazzola; Felipe von Glehn; Pia Kivisakk; Sheena L Dupuy; Gloria Kim; Tanuja Chitnis; Howard L Weiner; Roopali Gandhi; Rohit Bakshi Journal: JAMA Neurol Date: 2017-03-01 Impact factor: 18.302